The grant will support a global health research project conducted by Rajan George, the chief technology officer of Paladin Biosciences, titled 'dendritic cell receptor-targeted malaria vaccines'.
To receive funding, Dr George showed in a two-page application how his idea falls outside current scientific paradigms and might lead to significant advances in global health.
Paladin Biosciences will use its proprietary Chimigen platform technology to produce a malaria vaccine that targets the parasite at various stages of the infection, and test the vaccine in the laboratory for immunogenicity.
The Chimigen platform technology is a dendritic cell receptor-targeted approach to produce highly immunogenic vaccine that induces both antibody and cell-mediated immune responses without the need for an adjuvant, the company said.
Dr George said: "We are honored to be selected for this Grand Challenges Explorations grant, and we look forward to applying our novel Chimigen platform technology to the development of a malaria vaccine that may one day make a real impact on global health. The Chimigen platform technology is currently being used by Paladin Biosciences to develop therapeutic agents for hepatitis B and C, alphavirus and influenza virus infections."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index